A third dose of a COVID-19 vaccine is highly effective in patients with cirrhosis, according to a new study.
The study, published in the journal Hepatology, looked at the efficacy of the Pfizer-BioNTech and Moderna vaccines in patients with cirrhosis.
Patients in the study were given two doses of either the Pfizer vaccine or the Moderna vaccine, with the third dose given four to eight weeks later.
The study found that the vaccine was highly effective in preventing COVID-19 in patients with cirrhosis.
There was also a significant decrease in the number of patients who required hospitalization for COVID-19.
“This is the first study to show that the COVID-19 vaccine is effective in preventing disease in patients with cirrhosis,” said lead author Dr. Jordan Feld.
“This is an important finding as patients with cirrhosis are at high risk for severe COVID-19 disease.”
The study also found that the vaccine was well-tolerated in patients with cirrhosis.
“This study provides further evidence that the COVID-19 vaccine is safe and effective in a vulnerable population,” said Dr. Feld.
The study was conducted by researchers at the University of Toronto and the University Health Network in Toronto, Canada.
A new study has found that the third dose of a COVID-19 vaccine is highly effective in patients with cirrhosis.
Cirrhosis is a condition in which the liver becomes scarred and damaged. It is a serious condition that can lead to liver failure.
Patients with cirrhosis are at an increased risk of developing severe COVID-19, and many have died from the virus.
The new study, which is published in the journal Hepatology, looked at data from more than 700 patients with cirrhosis who received the Pfizer or Moderna COVID-19 vaccine.
The researchers found that the third dose of the vaccine was associated with a 90% reduction in the risk of developing severe COVID-19.
This is an important finding, as it shows that the vaccine is highly effective in a population that is at a high risk of developing severe COVID-19.
The study also found that patients who received the third dose of the vaccine had a lower risk of hospitalization and death from COVID-19.
This is an important finding, as it shows that the vaccine can save lives in a population that is at a high risk of dying from COVID-19.
The study’s lead author, Dr. Jordan Feld, said that the findings “support the use of a third dose of Pfizer or Moderna vaccine in patients with cirrhosis.”
He added that the findings “highlight the importance of vaccinating patients with cirrhosis against COVID-19.”
The study’s authors say that the findings “support the use of a third dose of Pfizer or Moderna vaccine in patients with cirrhosis.”
They add that the findings “highlight the importance of vaccinating patients with cirrhosis against COVID-19.”
